Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (IMA950-106)
Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/ II Trial
Sponsor: University Hospital, Geneva
A PHASE1/PHASE2 clinical study on Glioblastoma Multiforme and Glioblastoma Multiforme of Brain, this trial is completed. The trial is conducted by University Hospital, Geneva and has accumulated 12 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Unknown → Completed
-
Jan 2025 — Jun 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Geneva
For direct contact, visit the study record on ClinicalTrials.gov .